Anthony C. Vernon

TL;DR: The literature on microglia activation across different psychiatric disorders is assessed, including post-mortem and in-vivo studies in humans and experimental studies in animals, and it is highlighted that not all psychiatric patients have microglial activation.

TL;DR: It is shown that schizophrenia-relevant behavioral abnormalities and increased inflammatory cytokine expression are associated with reduced prefrontal TSPO levels, and the common assumption that central low-grade inflammation in schizophrenia is mirrored by increased T SPO expression or ligand binding is challenged.

TL;DR: This is the first systematic whole-brain MRI study of the effects of APD, which highlights significant effects on the cortex, and provides a tractable method for linking in vivo MRI findings to their histopathological origins.

TL;DR: It is shown for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model, indicating that there are lower synaptic terminal protein levels in schizophrenia in vivo and that antipsychotics exposure is unlikely to account for them.